Estrogen receptor-positive (ER+) breast cancer, which makes up around 70% of all breast cancer cases, often becomes resistant to current hormone therapies. Now, researchers have designed and ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

Olema Pharmaceuticals palazestrant shows promise in late-stage trials for metastatic breast cancer with potential FDA ...

Use of alerts triggered by patient-reported outcome monitoring improved symptom control for patients with advanced breast cancer, according to results of the randomized PRO B trial.The approach ...

Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a ...

Fengting Yan, MD, PhD, discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer.

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.